7 unknown. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 7 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow SABR: new trials by email Literature Review of SABR trials Research Report on SABR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma Pembrolizumab, Stereotactic Ablative Radiotherapy, Nephrectomy - Renal Cell Carcinoma, Clear Cell, Somatic | Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 20 | 2022-02-08 | 2024-05-16 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) Sintilimab, SBRT, Platinum based chemotherapy - Head and Neck Squamous Cell Carcinoma, Metastases | Phase 2 | Unknown | Jun-Lin Yi, MD | 50 | 2021-12-01 | 2021-11-29 |
| Adjuvant Stereotactic Pelvic Irradiation in Endometrial Cancer SABR - Endometrial Cancer | Phase 2 | Unknown | King Saud University | 30 | 2020-01-16 | 2020-01-22 |
| HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer Real time High-Dose-Rate prostate brachytherapy in combination with stereotactic prostate radiotherapy - Prostatic Neoplasm | Phase 2 | Unknown | David Büchser | 50 | 2019-07-01 | 2020-08-24 |
| Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery SABR, SABR + pembrolizumab - NSCLC, Stage I | Phase 1 / Phase 2 | Unknown | Amsterdam UMC, location VUmc | 20 | 2018-03-01 | 2018-02-27 |
| Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases SBRT, Standard of Care - Prostate Cancer, Breast Cancer | Phase 2 / Phase 3 | Unknown | Royal Marsden NHS Foundation Trust | 245 | 2016-11-01 | 2019-08-21 |
| SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy SBRT, Immunological Agent, Immunological Factors - Lung Cancer Metastatic | Phase 2 | Unknown | The First Affiliated Hospital of Xiamen University | 48 | 2016-11-01 | 2016-11-29 |
Carcinoma, Non-Small-Cell Lung (2) · Prostatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
Amsterdam UMC, location VUmc (1) · David Büchser (1) · Jun-Lin Yi, MD (1) · King Saud University (1) · Peter MacCallum Cancer Centre, Australia (1) · Royal Marsden NHS Foundation Trust (1) · The First Affiliated Hospital of Xiamen University (1)
Australia (2) · China (2) · Saudi Arabia (1) · Spain (1) · United Kingdom (1)
A.J. de Langen, MD, PhD (1) · Alfonso Gomez-Iturriaga, MD, PhD (1) · E.F. Smit, MD, PhD (1) · Junlin Yi, MD (1) · Shankar Siva, A/Prof (1) · Vincent Khoo, MD (1)